APA

Mackay H. J., Buckanovich R. J., Hirte H., Correa R., Hoskins P., Biagi J., Martin L. P., Fleming G. F., Morgan R., Wang L., Polintan R. & Oza A. M. (20120713). A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. : Gynecologic oncology.

Chicago

Mackay H J, Buckanovich R J, Hirte H, Correa R, Hoskins P, Biagi J, Martin L P, Fleming G F, Morgan R, Wang L, Polintan R and Oza A M. 20120713. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. : Gynecologic oncology.

Harvard

Mackay H. J., Buckanovich R. J., Hirte H., Correa R., Hoskins P., Biagi J., Martin L. P., Fleming G. F., Morgan R., Wang L., Polintan R. and Oza A. M. (20120713). A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. : Gynecologic oncology.

MLA

Mackay H J, Buckanovich R J, Hirte H, Correa R, Hoskins P, Biagi J, Martin L P, Fleming G F, Morgan R, Wang L, Polintan R and Oza A M. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. : Gynecologic oncology. 20120713.